Loading…
Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma
: The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first‐line chemotherapy and to determine the efficacy of maintenance alpha‐interferon (α‐IFN) in multiple myeloma (MM). Between January 1985 and December 1994, a prospective t...
Saved in:
| Published in: | European journal of haematology 1997-08, Vol.59 (2), p.100-104 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3 |
| container_end_page | 104 |
| container_issue | 2 |
| container_start_page | 100 |
| container_title | European journal of haematology |
| container_volume | 59 |
| creator | Kars, Ayşe Çelik, İsmail Kansu, Emin Tekuzman, Gülten Özişik, Yavuz Güler, Nilüfer Barişta, İbrahim Güllü, İbrahim Yalçin, Şuayib Altundaǧ, Kadri Zengin, Nurullah Türker, Alev Hayran, Mutlu Baltali, Eşmen Firat, Dinçer |
| description | : The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first‐line chemotherapy and to determine the efficacy of maintenance alpha‐interferon (α‐IFN) in multiple myeloma (MM). Between January 1985 and December 1994, a prospective trial was performed in stage II and III MM patients. The study population received only VAD with no maintenance therapy before 1990 (n = 31), and those recruited after 1990 (n = 33) were planned to be maintained with α‐IFN (5 mU, 3 times per wk) during the plateau to a maximum of 2 yr. Median follow‐up duration (44 vs. 39 months), time to response (3.4 vs. 3.5 months) and rate of objective response (61.3%, 19/31 and 63.6%, 21/33) were similar in VAD‐only and VAD+IFN groups, respectively. The survival analyses revealed higher median progression‐free (39.6 vs. 12 months) and overall survival (65+ vs. 24 months) durations in VAD+IFN group compared to VAD‐only group. VAD regimen was well tolerated and IFN‐related side effects were reversible. These findings denote that IFN maintenance prolongs the duration of response obtained by VAD. |
| doi_str_mv | 10.1111/j.1600-0609.1997.tb00732.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79280658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79280658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3</originalsourceid><addsrcrecordid>eNqVkM2O0zAUhS0EGsrAIyBFCLFLsJ3EPyyQZoahAxpAoKEsrZv0mro4P9ip2r49iRp1jze2dL57rvUR8orRjI3n7TZjgtKUCqozprXMhopSmfPs8IgsztFjsqCa8rQoCvaUPItxSynlmskLcqG5zlUpF2T1BVw7YAttjcmwwQD9Mdm7YZOA7zeQTmGwGLo2sZ333d61vxPrQhxS71pMVlcfEtcmzc4PrveYNEf0XQPPyRMLPuKL-b4kPz_ePtzcpffflp9uru7TusgFT0tG1xWXhSxBFlSsGZeyAlFxKyjTlhUKeF3mVtWSWwVY6hKFkpVQwEAqzC_Jm1NvH7q_O4yDaVys0XtosdtFIzVXVJRqBN-dwDp0MQa0pg-ugXA0jJpJqtmayZyZzJlJqpmlmsM4_HLesqsaXJ9HZ4tj_nrOIdbgbRhtunjGuBSSKTZi70_Y3nk8_scHzO3nu_ExFqSnAhcHPJwLIPwxQuayNL--Ls335Q9BV9cPJs__AZDXot8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79280658</pqid></control><display><type>article</type><title>Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Kars, Ayşe ; Çelik, İsmail ; Kansu, Emin ; Tekuzman, Gülten ; Özişik, Yavuz ; Güler, Nilüfer ; Barişta, İbrahim ; Güllü, İbrahim ; Yalçin, Şuayib ; Altundaǧ, Kadri ; Zengin, Nurullah ; Türker, Alev ; Hayran, Mutlu ; Baltali, Eşmen ; Firat, Dinçer</creator><creatorcontrib>Kars, Ayşe ; Çelik, İsmail ; Kansu, Emin ; Tekuzman, Gülten ; Özişik, Yavuz ; Güler, Nilüfer ; Barişta, İbrahim ; Güllü, İbrahim ; Yalçin, Şuayib ; Altundaǧ, Kadri ; Zengin, Nurullah ; Türker, Alev ; Hayran, Mutlu ; Baltali, Eşmen ; Firat, Dinçer</creatorcontrib><description>: The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first‐line chemotherapy and to determine the efficacy of maintenance alpha‐interferon (α‐IFN) in multiple myeloma (MM). Between January 1985 and December 1994, a prospective trial was performed in stage II and III MM patients. The study population received only VAD with no maintenance therapy before 1990 (n = 31), and those recruited after 1990 (n = 33) were planned to be maintained with α‐IFN (5 mU, 3 times per wk) during the plateau to a maximum of 2 yr. Median follow‐up duration (44 vs. 39 months), time to response (3.4 vs. 3.5 months) and rate of objective response (61.3%, 19/31 and 63.6%, 21/33) were similar in VAD‐only and VAD+IFN groups, respectively. The survival analyses revealed higher median progression‐free (39.6 vs. 12 months) and overall survival (65+ vs. 24 months) durations in VAD+IFN group compared to VAD‐only group. VAD regimen was well tolerated and IFN‐related side effects were reversible. These findings denote that IFN maintenance prolongs the duration of response obtained by VAD.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/j.1600-0609.1997.tb00732.x</identifier><identifier>PMID: 9293857</identifier><identifier>CODEN: EJHAEC</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; alpha-interferon ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Dexamethasone ; Doxorubicin - administration & dosage ; Female ; Hematologic and hematopoietic diseases ; Humans ; induction ; Interferon alpha-2 ; Interferon-alpha - administration & dosage ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; maintenance ; Male ; Medical sciences ; Middle Aged ; multiple myeloma ; Multiple Myeloma - drug therapy ; Multivariate Analysis ; Recombinant Proteins ; Survival Analysis ; Time Factors ; VAD chemotherapy ; Vincristine - administration & dosage</subject><ispartof>European journal of haematology, 1997-08, Vol.59 (2), p.100-104</ispartof><rights>Munksgaard 1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3</citedby><cites>FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2767181$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9293857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kars, Ayşe</creatorcontrib><creatorcontrib>Çelik, İsmail</creatorcontrib><creatorcontrib>Kansu, Emin</creatorcontrib><creatorcontrib>Tekuzman, Gülten</creatorcontrib><creatorcontrib>Özişik, Yavuz</creatorcontrib><creatorcontrib>Güler, Nilüfer</creatorcontrib><creatorcontrib>Barişta, İbrahim</creatorcontrib><creatorcontrib>Güllü, İbrahim</creatorcontrib><creatorcontrib>Yalçin, Şuayib</creatorcontrib><creatorcontrib>Altundaǧ, Kadri</creatorcontrib><creatorcontrib>Zengin, Nurullah</creatorcontrib><creatorcontrib>Türker, Alev</creatorcontrib><creatorcontrib>Hayran, Mutlu</creatorcontrib><creatorcontrib>Baltali, Eşmen</creatorcontrib><creatorcontrib>Firat, Dinçer</creatorcontrib><title>Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>: The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first‐line chemotherapy and to determine the efficacy of maintenance alpha‐interferon (α‐IFN) in multiple myeloma (MM). Between January 1985 and December 1994, a prospective trial was performed in stage II and III MM patients. The study population received only VAD with no maintenance therapy before 1990 (n = 31), and those recruited after 1990 (n = 33) were planned to be maintained with α‐IFN (5 mU, 3 times per wk) during the plateau to a maximum of 2 yr. Median follow‐up duration (44 vs. 39 months), time to response (3.4 vs. 3.5 months) and rate of objective response (61.3%, 19/31 and 63.6%, 21/33) were similar in VAD‐only and VAD+IFN groups, respectively. The survival analyses revealed higher median progression‐free (39.6 vs. 12 months) and overall survival (65+ vs. 24 months) durations in VAD+IFN group compared to VAD‐only group. VAD regimen was well tolerated and IFN‐related side effects were reversible. These findings denote that IFN maintenance prolongs the duration of response obtained by VAD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>alpha-interferon</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dexamethasone</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>induction</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>maintenance</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multivariate Analysis</subject><subject>Recombinant Proteins</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>VAD chemotherapy</subject><subject>Vincristine - administration & dosage</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqVkM2O0zAUhS0EGsrAIyBFCLFLsJ3EPyyQZoahAxpAoKEsrZv0mro4P9ip2r49iRp1jze2dL57rvUR8orRjI3n7TZjgtKUCqozprXMhopSmfPs8IgsztFjsqCa8rQoCvaUPItxSynlmskLcqG5zlUpF2T1BVw7YAttjcmwwQD9Mdm7YZOA7zeQTmGwGLo2sZ333d61vxPrQhxS71pMVlcfEtcmzc4PrveYNEf0XQPPyRMLPuKL-b4kPz_ePtzcpffflp9uru7TusgFT0tG1xWXhSxBFlSsGZeyAlFxKyjTlhUKeF3mVtWSWwVY6hKFkpVQwEAqzC_Jm1NvH7q_O4yDaVys0XtosdtFIzVXVJRqBN-dwDp0MQa0pg-ugXA0jJpJqtmayZyZzJlJqpmlmsM4_HLesqsaXJ9HZ4tj_nrOIdbgbRhtunjGuBSSKTZi70_Y3nk8_scHzO3nu_ExFqSnAhcHPJwLIPwxQuayNL--Ls335Q9BV9cPJs__AZDXot8</recordid><startdate>199708</startdate><enddate>199708</enddate><creator>Kars, Ayşe</creator><creator>Çelik, İsmail</creator><creator>Kansu, Emin</creator><creator>Tekuzman, Gülten</creator><creator>Özişik, Yavuz</creator><creator>Güler, Nilüfer</creator><creator>Barişta, İbrahim</creator><creator>Güllü, İbrahim</creator><creator>Yalçin, Şuayib</creator><creator>Altundaǧ, Kadri</creator><creator>Zengin, Nurullah</creator><creator>Türker, Alev</creator><creator>Hayran, Mutlu</creator><creator>Baltali, Eşmen</creator><creator>Firat, Dinçer</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199708</creationdate><title>Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma</title><author>Kars, Ayşe ; Çelik, İsmail ; Kansu, Emin ; Tekuzman, Gülten ; Özişik, Yavuz ; Güler, Nilüfer ; Barişta, İbrahim ; Güllü, İbrahim ; Yalçin, Şuayib ; Altundaǧ, Kadri ; Zengin, Nurullah ; Türker, Alev ; Hayran, Mutlu ; Baltali, Eşmen ; Firat, Dinçer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>alpha-interferon</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dexamethasone</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>induction</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>maintenance</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multivariate Analysis</topic><topic>Recombinant Proteins</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>VAD chemotherapy</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kars, Ayşe</creatorcontrib><creatorcontrib>Çelik, İsmail</creatorcontrib><creatorcontrib>Kansu, Emin</creatorcontrib><creatorcontrib>Tekuzman, Gülten</creatorcontrib><creatorcontrib>Özişik, Yavuz</creatorcontrib><creatorcontrib>Güler, Nilüfer</creatorcontrib><creatorcontrib>Barişta, İbrahim</creatorcontrib><creatorcontrib>Güllü, İbrahim</creatorcontrib><creatorcontrib>Yalçin, Şuayib</creatorcontrib><creatorcontrib>Altundaǧ, Kadri</creatorcontrib><creatorcontrib>Zengin, Nurullah</creatorcontrib><creatorcontrib>Türker, Alev</creatorcontrib><creatorcontrib>Hayran, Mutlu</creatorcontrib><creatorcontrib>Baltali, Eşmen</creatorcontrib><creatorcontrib>Firat, Dinçer</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kars, Ayşe</au><au>Çelik, İsmail</au><au>Kansu, Emin</au><au>Tekuzman, Gülten</au><au>Özişik, Yavuz</au><au>Güler, Nilüfer</au><au>Barişta, İbrahim</au><au>Güllü, İbrahim</au><au>Yalçin, Şuayib</au><au>Altundaǧ, Kadri</au><au>Zengin, Nurullah</au><au>Türker, Alev</au><au>Hayran, Mutlu</au><au>Baltali, Eşmen</au><au>Firat, Dinçer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>1997-08</date><risdate>1997</risdate><volume>59</volume><issue>2</issue><spage>100</spage><epage>104</epage><pages>100-104</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><coden>EJHAEC</coden><abstract>: The aim of this study was to evaluate the response characteristics of vincristine, adriamycin and dexamethasone (VAD) as a first‐line chemotherapy and to determine the efficacy of maintenance alpha‐interferon (α‐IFN) in multiple myeloma (MM). Between January 1985 and December 1994, a prospective trial was performed in stage II and III MM patients. The study population received only VAD with no maintenance therapy before 1990 (n = 31), and those recruited after 1990 (n = 33) were planned to be maintained with α‐IFN (5 mU, 3 times per wk) during the plateau to a maximum of 2 yr. Median follow‐up duration (44 vs. 39 months), time to response (3.4 vs. 3.5 months) and rate of objective response (61.3%, 19/31 and 63.6%, 21/33) were similar in VAD‐only and VAD+IFN groups, respectively. The survival analyses revealed higher median progression‐free (39.6 vs. 12 months) and overall survival (65+ vs. 24 months) durations in VAD+IFN group compared to VAD‐only group. VAD regimen was well tolerated and IFN‐related side effects were reversible. These findings denote that IFN maintenance prolongs the duration of response obtained by VAD.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9293857</pmid><doi>10.1111/j.1600-0609.1997.tb00732.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 1997-08, Vol.59 (2), p.100-104 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79280658 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adolescent Adult Aged alpha-interferon Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Dexamethasone Doxorubicin - administration & dosage Female Hematologic and hematopoietic diseases Humans induction Interferon alpha-2 Interferon-alpha - administration & dosage Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis maintenance Male Medical sciences Middle Aged multiple myeloma Multiple Myeloma - drug therapy Multivariate Analysis Recombinant Proteins Survival Analysis Time Factors VAD chemotherapy Vincristine - administration & dosage |
| title | Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A39%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintenance%20therapy%20with%20alpha-interferon%20following%20first-line%20VAD%20in%20multiple%20myeloma&rft.jtitle=European%20journal%20of%20haematology&rft.au=Kars,%20Ay%C5%9Fe&rft.date=1997-08&rft.volume=59&rft.issue=2&rft.spage=100&rft.epage=104&rft.pages=100-104&rft.issn=0902-4441&rft.eissn=1600-0609&rft.coden=EJHAEC&rft_id=info:doi/10.1111/j.1600-0609.1997.tb00732.x&rft_dat=%3Cproquest_cross%3E79280658%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4362-510db27475a7406d1277ba6b2f6019f148a2c53f8c72f8ae595e687b68a1a78e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79280658&rft_id=info:pmid/9293857&rfr_iscdi=true |